CRMD earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E 3.34. Updated 2026-07-23.
CorMedix (CRMD) Research Hub
CorMedix (CRMD) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 7.825 USD (-3.75%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 3.34, market cap 0.62B. This hub links to the full technical, earnings and options research available for CRMD.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.825 USD (-3.75%) |
| 52-week range | 7.13 USD – 9.06 USD |
| Trend regime | Range |
| 14-day RSI | 54.7 (Neutral) |
| Trailing P/E | 3.34 |
| Market cap | 0.62B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for CRMD
Covered Call on CRMD: how it works, illustrative setup around the real 7.83 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CRMD: how it works, illustrative setup around the real 7.83 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CRMD: how it works, illustrative setup around the real 7.83 USD price, max profit/loss, breakeven and when to use it. Educational.
CRMD technical analysis: range, last 7.825 USD, RSI 54.7, 52w range 7.13 USD–9.06 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CRMD in?
CorMedix (CRMD) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CRMD in an uptrend or downtrend?
As of 2026-09-11, CRMD is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CRMD's trailing P/E ratio?
CRMD's trailing P/E is 3.34, with a market cap of 0.62B. See the earnings research page for full valuation detail.
When does CRMD next report earnings?
CRMD is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of 0.26 USD.